pharmaphorum2d
Novo Nordisk’s diabetes treatments approved in EU
FlexTouch, which has an easy auto-injector mechanism. “These marketing authorisations constitute significant milestones for Novo Nordisk and the treatment of diabetes. We look forward to making ...
Will Medicare End Ozempic Maker Novo Nordisk's Obesity Drug Boom?
Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...
pharmaphorum2d
Novo Nordisk launches recycling programme for pen injectors
The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch devices, which are used to dispense insulin and other medications. Users of the devices in the UK will shortly be able to ...
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said on Friday a late-stage trial with a high-dose version of its weight loss drug semaglutide helped overweight ...
Hosted on MSN4d
Novo Nordisk Stock Tumbles As Ozempic Faces US Pricing Scrutiny, Semaglutide Trial Underwhelms: Retail Gets Anxious
Novo Nordisk A/S shares fell over 4% premarket Friday, heading for lows last seen in early August, amid concerns over pricing ...
Novo Nordisk: STEP UP Trial Achieves Primary Endpoint - Quick Facts
Novo Nordisk (NVO) reported headline results from STEP UP, a phase 3b trial in the global STEP programme. The trial achieved primary ...
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...